AR032895A1 - Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina - Google Patents

Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina

Info

Publication number
AR032895A1
AR032895A1 ARP010104402A ARP010104402A AR032895A1 AR 032895 A1 AR032895 A1 AR 032895A1 AR P010104402 A ARP010104402 A AR P010104402A AR P010104402 A ARP010104402 A AR P010104402A AR 032895 A1 AR032895 A1 AR 032895A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
substituted
hydrogen
independently selected
Prior art date
Application number
ARP010104402A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR032895A1 publication Critical patent/AR032895A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto imidazol sustituido, incluyendo enantiomeros, estereoisomeros y tautomeros del mismo, o sales o solvatos farmacéuticamente aceptables de dicho compuesto, en donde dicho compuesto tiene la estructura general que se muestra en la formula (1) en la cual G está seleccionado del grupo que consiste en alquilo C1-6 o un enlace; M es una porcion seleccionada del grupo que consiste en ûC=C, -CsC-, -C(=NR7)-NR6-, -NR6-C(=NR7)-, -NR6-C(O)-NR6-, -NR6-C(O)-O-, -O-C(O)-NR6-, -NR6-C(O)-, -C(O)-NR6-, -O-, -NR6-, -C(O)-, N+R6R8-, y en la formula (2) p es 1-6; V es alquilo C1-6; X e Y pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste en N, CH o N-oxido, con la condicion de que por lo menos uno de X e Y es N o N-oxido; R1 y R2 pueden ser cada uno el numero 1-4 y están independientemente seleccionados del grupo que consiste en hidrogeno, alquilo inferior, alcoxi inferior, halogeno, polihaloalquilo inferior, -OH, -N(R6)2, -NO2, -CN, -COOR6, -CONR6R8, y ûNR6-C(O)-R7 (donde R7 no es ûOH o ûCN); R3 está seleccionado entre hidrogeno, alquilo inferior, alcoxi inferior, hidroxilo, polihaloalquilo inferior, y un enlace que forma un doble enlace hacia la porcion G cuando G es alquilo C1-6; R4 y R5 están independientemente seleccionados del grupo que consiste en hidrogeno, alquilo inferior, y polihaloalquilo inferior; R6 y R8 están independientemente seleccionados entre hidrogeno, alquilo inferior, aralquilo, alquilarilo, polihaloalquilo inferior, fenilo sustituido o no sustituido; y bencilo sustituido o no sustituido; y R7 está seleccionado entre H, OH, alcoxi, ciano, fenilo, fenilo sustituido, bencilo y bencilo sustituido; con la condicion de que cuando G es un enlace M no es ûNR6C(O)-, y con la condicion de que cuando G es un enlace y M es ûO- o ûO-C(O)-NR6-, entonces uno de X e Y es N; y con la condicion adicional de que cuando R3 es ûOH o alcoxilo, y G es un enlace, entonces M a O o NR6. En otra realizacion se describen composiciones farmacéuticas que comprenden dichos imidazoles así como también el uso de los mismos para la manufactura de un medicamento para tratar alergia, enfermedades inflamatorias y enfermedades relacionadas con el SNC y otras.
ARP010104402A 2000-09-20 2001-09-18 Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina AR032895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23404000P 2000-09-20 2000-09-20

Publications (1)

Publication Number Publication Date
AR032895A1 true AR032895A1 (es) 2003-12-03

Family

ID=22879630

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104402A AR032895A1 (es) 2000-09-20 2001-09-18 Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina

Country Status (14)

Country Link
US (1) US6518287B2 (es)
EP (1) EP1318983B1 (es)
JP (1) JP2004509870A (es)
CN (1) CN1461299A (es)
AR (1) AR032895A1 (es)
AT (1) ATE411983T1 (es)
AU (1) AU2001292723A1 (es)
CA (1) CA2421823A1 (es)
DE (1) DE60136284D1 (es)
ES (1) ES2313985T3 (es)
HK (1) HK1052181A1 (es)
MX (1) MXPA03002447A (es)
MY (1) MY129677A (es)
WO (1) WO2002024658A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
BRPI0514857A (pt) 2004-09-03 2008-05-06 Celgene Corp composto ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para inibir a angiogênese, para inibir ou reduzir a polimerização da tubulina ou a estabilidade da tubulina em uma célula, para inibir a atividade de pde4 em uma célula, para inibir atividade do fator-alfa de necrose de tumor (tnf-alfa) em uma célula, para tratar ou melhorar um distúrbio inflamatório, para tratar ou melhorar cáncer, para inibir a proliferação de célula cancerosa, para marcar, bloquear ou destruir a função de vasculatura tumoral, para marcar, bloquear ou destruir o endotélio de vasos tumor, para marcar, bloquear ou destruir a função de vasculatura tumoral e inibir a angiogênese em um tumor e para tratar ou melhorar um distúrbio do sistema nervoso central
WO2007077510A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3512084A1 (de) * 1985-04-02 1986-10-09 Ludwig Heumann & Co GmbH, 8500 Nürnberg Guanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
DE3631334A1 (de) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
DK0448765T3 (da) 1990-03-30 1994-09-19 Heumann Pharma Gmbh & Co Anvendelse af guanidinderivater til fremstilling af et lægemiddel med NPY-antagonistisk virkning
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
DK0618905T3 (da) 1991-12-18 1995-12-04 Schering Corp Imidazolyl-alkyl-piperazin- og -diazepinderivater som histamin H3-agonister/antagonister
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
ATE214604T1 (de) 1997-06-24 2002-04-15 Novo Nordisk As Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheiten
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6211182B1 (en) * 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms

Also Published As

Publication number Publication date
AU2001292723A1 (en) 2002-04-02
CA2421823A1 (en) 2002-03-28
MXPA03002447A (es) 2003-07-21
HK1052181A1 (zh) 2003-09-05
WO2002024658A3 (en) 2002-07-11
WO2002024658A2 (en) 2002-03-28
MY129677A (en) 2007-04-30
CN1461299A (zh) 2003-12-10
ES2313985T3 (es) 2009-03-16
EP1318983A2 (en) 2003-06-18
US6518287B2 (en) 2003-02-11
ATE411983T1 (de) 2008-11-15
US20020103235A1 (en) 2002-08-01
DE60136284D1 (de) 2008-12-04
EP1318983B1 (en) 2008-10-22
JP2004509870A (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
AR056980A1 (es) Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
PE20060653A1 (es) Derivados triciclicos condensados como moduladores del receptor 5-ht1
DE602004016516D1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
PE20010528A1 (es) Uso de antagonistas del factor liberador de corticotropina (corticoliberina o crf) y composiciones relacionadas
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
AR033046A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1, composicion farmaceutica y metodos de preparacion
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR035716A1 (es) Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
PE20020616A1 (es) Compuestos de piperidina como antagonistas del receptor ccr-3
AR033735A1 (es) Compuestos de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
PA8621501A1 (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
ATE455103T1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
DE602004020638D1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
AR016433A1 (es) Procedimiento para el tratamiento de la impotencia y composiciones.
ATE260275T1 (de) Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one
UY25857A1 (es) 4-alquenil (y alquinil) oxindoles los cuales inhiben las quinasas dependientes de ciclina (cdks)
DE69903333T2 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
AR042733A1 (es) Derivados de piridinas utilizados como inhibidores del mecanismo de intercambio na+/ca2+
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas
CA2745699A1 (en) Substituted benzyl and phenylsulfonyl triazolones, and use thereof
AR032895A1 (es) Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina

Legal Events

Date Code Title Description
FB Suspension of granting procedure